Persistent Asset Partners’s enGene Therapeutics ENGN Stock Holding History

Persistent Asset Partners’s Portfolio ENGN Stock Details ENGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$198K	Buy	+114,493	New	+$467K	0.06%	217

Other funds holding ENGN

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return

Marquette Asset Management Minneapolis, Minnesota $779M AUM 23.4% 1-Year Est. Return

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Fountainhead AM Warren, New Jersey $135M AUM 24.26% 1-Year Est. Return

PFS Partners Mine Hill, New Jersey $247M AUM 29.02% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Persistent Asset Partners's ENGN Position: Q2 2026 in Review

Persistent Asset Partners opened a new position in enGene Therapeutics (ENGN) in Q2 2026: 114,493 shares worth $198K. The stake represents 0.06% of the portfolio and ranks #217 among its holdings.

11 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

Persistent Asset Partners held 114,493 shares of enGene Therapeutics worth $198K as of Q2 2026.
enGene Therapeutics was a new Persistent Asset Partners position in Q2 2026.
enGene Therapeutics made up 0.06% of Persistent Asset Partners's portfolio in Q2 2026, its #217 holding.
11 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.